The effects of liraglutide in controlling blood sugar and weight in poor-responders to bariatric surgery

Not Applicable

Completed

• Conditions: Topic: Diabetes, Metabolic and endocrine disorders; Subtopic: Type 2, Metabolic and Endocrine (all Subtopics); Disease: Diabetic Control, Metabolic & Endocrine (not diabetes); Nutritional, Metabolic, Endocrine; 1. Obesity 2. Diabetes

• Registration Number: ISRCTN13643081
• Lead Sponsor: Imperial College London

Brief Summary

2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31174993 (added 10/06/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-01-20
• Study Completion: 2019-02-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Aged between 18­ and 70 years
2. 12 months after gastric bypass or sleeve gastrectomy bariatric surgery
3. Diagnosed with Type 2 diabetes mellitus
4. HbA1c greater than 6.5% (more than 48 mmol/mol) on screening
5. On Metformin ± long acting insulin
6. Able to give informed consent

Exclusion Criteria

1. Diagnosis of Type 1 diabetes mellitus
2. Anatomical or endocrinological pathology causing poor weight loss or weight regain
3. Screening calcitonin of 50 ng/L or above
4. Family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
5. Personal history of non­familial medullary thyroid carcinoma
6. History of acute or chronic pancreatitis
7. Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100
mmHg or above)
8. Estimated glomerular filtration rate (eGFR) less than30 ml/min per 1.73 m2
9. Current pregnancy
10. Inability to maintain adequate contraception

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diabetes management is assessed by measuring glycated hemoglobin (HbA1C) at baseline and 26 weeks.